Oramed Pharmaceuticals Inc.
ORMPNasdaqCIK 1176309HealthcareFiscal year ends Dec 31
Reports and events: 333 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-1719:37 ET | 8-K | 5.07 Shareholder vote results | 0001213900-26-100929 |
| 2026-08-1021:29 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001213900-26-087361 |
| 2026-08-0320:05 ET | DEF 14A | Proxy statementPeriod 2026-09-15 | 0001213900-26-084609 |
| 2026-07-2216:15 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001213900-26-080406 |
| 2026-06-3020:19 ET | 8-K | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-073709 |
| 2026-06-1720:48 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001213900-26-069783 |
| 2026-05-1921:08 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001213900-26-059112 |
| 2026-05-1417:19 ET | SCHEDULE 13D | Ownership report, active investor | 0001213900-26-056837 |
| 2026-03-3120:20 ET | 8-K | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition | 0001213900-26-037474 |
| 2026-03-2621:14 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001213900-26-034835 |
| 2026-02-2021:26 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001012975-26-000195 |
| 2026-02-1921:50 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001213900-26-018576 |
| 2026-01-2916:44 ET | SCHEDULE 13D | Ownership report, active investor | 0001213900-26-009570 |
| 2026-01-1421:31 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-004382 |
| 2026-01-0713:56 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-001983 |
| 2025-12-3121:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001213900-25-127133 |
| 2025-12-3101:51 ET | 8-K | 8.01 Other events | 0001012975-25-000992 |
| 2025-11-1714:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-25-111310 |
| 2025-11-1713:50 ET | 8-K | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 9.01 Financial statements and exhibits | 0001213900-25-111298 |
| 2025-11-1321:07 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001213900-25-109980 |
| 2025-10-2423:39 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-101825 |
| 2025-10-0613:28 ET | 8-K | 8.01 Other events | 0001213900-25-096322 |
| 2025-08-2820:01 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001213900-25-081720 |
| 2025-08-2120:06 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001213900-25-079361 |
| 2025-08-1420:11 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001213900-25-076668 |
| 2025-07-2312:36 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-066819 |
| 2025-07-1621:08 ET | DEF 14A | Proxy statementPeriod 2025-08-19 | 0001213900-25-064755 |
| 2025-07-1620:05 ET | 10-K/A | Annual report, amendedPeriod 2024-12-31 | 0001213900-25-064678 |
| 2025-05-2120:05 ET | 8-K | 8.01 Other events | 0001213900-25-046436 |
| 2025-05-1520:06 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001213900-25-044193 |
| 2025-05-0113:59 ET | SCHEDULE 13D | Ownership report, active investor | 0001213900-25-038294 |
| 2025-04-2820:30 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-25-036109 |
| 2025-03-2721:00 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001013762-25-003450 |
| 2025-03-0321:30 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-25-019437 |
| 2025-02-2722:00 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-25-018135 |
| 2025-02-1121:35 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-25-012244 |
| 2025-01-2214:18 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-25-005212 |
| 2025-01-0313:31 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-25-000517 |
| 2024-12-1721:55 ET | 8-K | 8.01 Other events | 0001213900-24-109825 |
| 2024-11-0721:05 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001213900-24-095397 |
| 2024-10-2921:01 ET | 8-K | 8.01 Other events | 0001213900-24-091795 |
| 2024-10-0818:12 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-086214 |
| 2024-09-2620:05 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-24-082237 |
| 2024-09-2312:06 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-080812 |
| 2024-08-1420:05 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001213900-24-068992 |
| 2024-08-0220:05 ET | 8-K | 5.07 Shareholder vote results | 0001213900-24-064732 |
| 2024-06-2613:00 ET | 8-K | 8.01 Other events | 0001213900-24-055950 |
| 2024-06-2413:00 ET | 8-K | 8.01 Other events | 0001213900-24-055006 |
| 2024-06-2011:30 ET | DEF 14A | Proxy statementPeriod 2024-08-01 | 0001213900-24-054007 |
| 2024-06-1021:28 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001213900-24-051355 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:06 ET. Listed shows no prices and gives no investment advice.